Results 61 to 70 of about 213,637 (257)

CHST1 Drives Immunotherapy Resistance in Triple‐Negative Breast Cancer by Orchestrating an Immunosuppressive Microenvironment via the NKRF–CCL20–Macrophage Axis

open access: yesAdvanced Science, EarlyView.
Proposed model of CHST1‐associated immune remodeling in triple‐negative breast cancer. In CHST1‐low tumors, greater nuclear accumulation of NKRF is associated with repression of an NF‐κB‐related CCL20 transcriptional program and an immune‐inflamed microenvironment.
Shu‐Hao Jiang   +6 more
wiley   +1 more source

Carrier‐Free Stimulus‐Responsive Theranostic Nanoprodrug Enabling GSH‐Consumption‐Promoted Chemo‐Photodynamic Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Leveraging the critical role of glutathione (GSH) in mediating drug resistance and scavenging reactive oxygen species (ROS) in cancer cells, a carrier‐free GSH‐consuming theranostic nanoprodrug, consisting of a BODIPY photosensitizer and the chemotherapeutic drug paclitaxel linked through a GSH‐consuming drug linker, is developed to deeply explore the ...
Hansheng Huang, Binglin Sui
wiley   +1 more source

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel

open access: yesInternational Journal of Nanomedicine, 2013
Neha Gupta, Hassan Hatoum, Grace K DyDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USAAbstract: Lung cancer is the leading cause of cancer mortality worldwide in both men and women.
Gupta N, Hatoum H, Dy GK
doaj  

YTHDC1 Orchestrates Glucose and Glutamate Rewiring to Overcome Lethal Metabolic Stress in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
Lai et al. find that m6A reader YTHDC1 is specifically overexpressed in triple‐negative breast cancer (TNBC) and orchestrates glucose and glutamine metabolism in an m6A‐dependent manner to confer robust adaptability to lethal metabolic stress. Leveraging YTHDC1 knockdown‐induced metabolic vulnerability, an ATF4 mRNA‐targeted nanotherapy is developed to
Zheng‐Hao Lai   +12 more
wiley   +1 more source

FoxM1 Induced Paclitaxel Resistance via Activation of the FoxM1/PHB1/RAF-MEK-ERK Pathway and Enhancement of the ABCA2 Transporter

open access: yesMolecular Therapy: Oncolytics, 2019
FoxM1 amplification in human pancreatic cancer predicts poor prognosis and resistance to paclitaxel. Here, a novel role between FoxM1 (FoxM1b and FoxM1c) and Prohibitin1 (PHB1) in paclitaxel resistance has been identified.
Chao Huang   +5 more
doaj   +1 more source

Epigenetic Reactivation of TNFRSF19 Suppresses Mitophagy and Sensitizes Triple‐Negative Breast Cancer to Doxorubicin

open access: yesAdvanced Science, EarlyView.
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu   +7 more
wiley   +1 more source

Proinflammatory Factors Mediate Paclitaxel-Induced Impairment of Learning and Memory

open access: yesMediators of Inflammation, 2018
The chemotherapeutic agent paclitaxel is widely used for cancer treatment. Paclitaxel treatment impairs learning and memory function, a side effect that reduces the quality of life of cancer survivors. However, the neural mechanisms underlying paclitaxel-
Zhao Li   +6 more
doaj   +1 more source

Enhancement of paclitaxel transport and cytotoxicity by 7,3’,4’-trimethoxyflavone, a P-glycoprotein inhibitor

open access: yesJournal of Pharmacy & Pharmaceutical Sciences, 2007
Purpose.: Paclitaxel has problems with respect to bioavailability and resistance. The aim of this study was to select a P-glycoprotein (Pgp)- inhibitory flavonoid to enhance paclitaxel bioavailability in the Caco-2 cell monolayer. Methods.
Ju-Mi Jeong, Cheol-Hee Choi
doaj   +1 more source

Ultrasound‐Activated Nanoinhibitors Blocking the Chemo‐Immune Checkpoint to Overcome Chemotherapy‐Induced Immune Resistance

open access: yesAdvanced Science, EarlyView.
A sono‐responsive chemo‐immune checkpoint nanoinhibitor (Sono‐TT8) co‐delivering TPZ chemotherapy and siXkr8 simultaneously kills tumor cells and blocks PS externalization, reversing chemotherapy‐induced immunosuppression and enhancing antitumor immunity. ABSTRACT Breast cancer features an immunosuppressive tumor microenvironment following chemotherapy
Yunfan Liu   +13 more
wiley   +1 more source

Deguelin Restores Paclitaxel Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells via Inhibition of the EGFR Signaling Pathway [PDF]

open access: yes
Seunghee Bae,1 Sowon Bae,1 Hee Su Kim,1 Ye Jin Lim,1 Gyeongmi Kim,2 In-Chul Park,2 Kyeong A So,3 Tae Jin Kim,3 Jae Ho Lee1 1Department of Cosmetics Engineering, Konkuk University, Seoul, 05029, Republic of Korea; 2Division of Fusion Radiology Research ...
Park IC   +7 more
core  

Home - About - Disclaimer - Privacy